source
- Chutes & Ladders—Neumora shuffles leadership ahead of INDJoshua Pinto, Ph.D., has been appointed chief executive officer of Neumora Therapeutics, a clinical-stage biotech with obesity and neuro assets.Fierce Biotech · 23h ago↗ source
- BioMarin to acquire Alesta Therapeutics for $275 million to expand bone disease pipelineBioMarin Pharmaceutical announced it will purchase Alesta Therapeutics for an upfront payment of $275 million. Alesta is developing an oral small-molecule drug, ALE1, aimed at treating hypophospha…